BMS 986458
Alternative Names: BCL6 LDD; BMS-986458Latest Information Update: 13 Mar 2026
At a glance
- Originator Bristol-Myers Squibb
- Class Amines; Antineoplastics; Chlorinated hydrocarbons; Indazoles; Indoles; Ketones; Piperidines; Pyrimidines; Small molecules
- Mechanism of Action BCL6 protein degraders
-
Orphan Drug Status
No
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity Yes
Highest Development Phases
- Phase I/II Non-Hodgkin's lymphoma
Most Recent Events
- 13 Mar 2026 Chemical structure information added.
- 08 Dec 2025 Efficacy and adverse events data from phase I/II clinical trials in Non-Hodgkin's lymphoma released by Bristol Myers Squibb
- 06 Dec 2025 Efficacy, adverse event and pharmacodynamics data from phase-I/II clinical trials in Non-Hodgkin's lymphoma presented at the 67th American Society of Hematology Annual Meeting and Exposition (ASH-Hem-2025)